Navidea Biopharmaceuticals CEO Jed Latkin's 2021 pay rises 10% to $1.3M
Navidea Biopharmaceuticals reports 2021 executive compensation
By ExecPay News
Published: October 24, 2022
Navidea Biopharmaceuticals reported fiscal year 2021 executive compensation information on October 24, 2022.
In 2021, five executives at Navidea Biopharmaceuticals received on average a compensation package of $471K, a 7% decrease compared to previous year.
Average pay of disclosed executives at Navidea Biopharmaceuticals
Jed A. Latkin, Chief Executive Officer, received $1.3M in total, which increased by 10% compared to 2020.
Michael S. Rosol, Chief Medical Officer, received a compensation package of $469K, which increased by 56% compared to previous year. 56% of the compensation package, or $264K, was in salary.
Erika L. Eves, Vice President, Finance & Administration, earned $237K in 2021, a 33% increase compared to previous year.
Michel Mikhail, Chief Regulatory Officer, received $153K in 2021.
Joel H. Kaufman, Former Chief Business Officer, earned $147K in 2021, a 55% decrease compared to previous year.
Related executives
Michael Rosol
Navidea Biopharmaceuticals
Chief Medical Officer
Michel Mikhail
Navidea Biopharmaceuticals
Chief Regulatory Officer
Erika Eves
Navidea Biopharmaceuticals
Vice President, Finance & Administration
Jed Latkin
Navidea Biopharmaceuticals
Chief Executive Officer
Joel Kaufman
Navidea Biopharmaceuticals
Former Chief Business Officer
You may also like
Source: SEC filing on October 24, 2022.